Gefitinib, erlotinib, and afatinib have been proven to improve progression-free survival (PFS) in patients with advanced EGFR-mutant NSCLC compared with platinum-based chemotherapy [5,6,12]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.